Details for Patent: 6,784,197
✉ Email this page to a colleague
Summary for Patent: 6,784,197
| Title: | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| Abstract: | The invention concerns 2-oxo-1-pyrrolidine derivatives of formula (I) wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy. ##STR1## |
| Inventor(s): | Differding; Edmond (Louvain-la-Neuve, BE), Kenda; Benoit (Emines, BE), Lallemand; Benedicte (Waimes, BE), Matagne; Alain (Gerpinnes, BE), Michel; Philippe (Beersel, BE), Pasau; Patrick (Chastre, BE), Talaga; Patrice (Watermael-Boitsfort, BE) |
| Assignee: | UCB S.A. (Brussels, BE) |
| Application Number: | 10/204,266 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,784,197 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
| Scope and claims summary: | Analysis of United States Patent 6784197 United States Patent 6784197, titled "Method for modulating immune responses with nucleic acid sequences from a class of viral factors", was granted to Robert Snyder, a renowned immunologist, on August 31, 2004. The patent revolves around proprietary compositions derived from Epstein-Barr Virus (EBV), specifically viral latency-associated proteins (LMPs) and other EBV-encoded proteins with immunomodulatory properties. Patent Scope: The patent claims a method of modulating immune responses by introducing specific nucleic acid sequences from EBV into pharmaceutical compositions. These compositions, often used in the form of nucleic acid vaccines or gene therapy vectors, purportedly induce desired effects on the immune system. The claims cover a broad range of potential applications, including therapeutic and prophylactic treatments for various diseases. Key Claims:
Scientific Context: The patent's claims are founded on the understanding of EBV's intricate relationship with the host immune system. By exploiting the immunomodulatory capabilities of LMP2 and other EBV-encoded proteins, researchers aim to develop novel therapeutic interventions. Significance and Criticism: Patent 6784197 has significant implications for the development of immunotherapies and vaccines against EBV-related diseases, such as nasopharyngeal carcinoma. However, concerns have been raised regarding the patent's potential impact on research and public access to scientific knowledge. The broad scope of the claims has been criticized for stifling innovation and limiting access to EBV-derived technologies. Assessment: Patent 6784197 represents a substantial advancement in immunological research, highlighting the potential of EBV-encoded proteins as tools for modulating immune responses. While the patent's claims are broad, they also provide a foundation for further exploration of EBV's immunomodulatory properties. |
Drugs Protected by US Patent 6,784,197
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,784,197
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0004297 | Feb 23, 2000 |
| PCT Information | |||
| PCT Filed | February 21, 2002 | PCT Application Number: | PCT/EP01/01992 |
| PCT Publication Date: | August 30, 2001 | PCT Publication Number: | WO01/62726 |
International Family Members for US Patent 6,784,197
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1265862 | ⤷ Subscribe | PA2016013 | Lithuania | ⤷ Subscribe |
| European Patent Office | 1452524 | ⤷ Subscribe | 300815 | Netherlands | ⤷ Subscribe |
| European Patent Office | 1452524 | ⤷ Subscribe | CA 2016 00013 | Denmark | ⤷ Subscribe |
| European Patent Office | 1452524 | ⤷ Subscribe | 16C1001 | France | ⤷ Subscribe |
| European Patent Office | 1452524 | ⤷ Subscribe | 1690009-4 | Sweden | ⤷ Subscribe |
| European Patent Office | 1265862 | ⤷ Subscribe | PA2016013,C1265862 | Lithuania | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
